PROACT
Phase 2 Terminated
49 enrolled 12 charts
A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives
Phase 2 Terminated
4 enrolled 8 charts
ClaSPd
Phase 2 Terminated
4 enrolled 9 charts
A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
Phase 2 Terminated
7 enrolled 5 charts
PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma
Phase 2 Terminated
6 enrolled
AntiCD-66
Phase 2 Terminated
25 enrolled
Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients
Phase 2 Terminated
9 enrolled 6 charts
Arsenic Trioxide in Treating Patients With Multiple Myeloma
Phase 2 Terminated
Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple Myeloma
Phase 2 Terminated
Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy
Phase 2 Terminated
342 enrolled 14 charts
Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma
Phase 2 Terminated
11 enrolled 9 charts
Study of Immune Response Modifier in the Treatment of Hematologic Malignancies
Phase 2 Terminated
6 enrolled 8 charts
Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
Phase 2 Terminated
4 enrolled 4 charts
DexTR
Phase 2 Terminated
5 enrolled 8 charts
Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant
Phase 2 Terminated
2 enrolled 7 charts
Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma
Phase 2 Terminated
24 enrolled 3 charts
Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant
Phase 2 Terminated
4 enrolled 5 charts
Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma
Phase 2 Terminated
87 enrolled
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
Phase 2 Terminated
200 enrolled 11 charts
Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies
Phase 2 Terminated
13 enrolled 12 charts
Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease
Phase 2 Terminated
13 enrolled 24 charts
Anti-thymocyte Globulin and Melphalan in Treating Patients With Relapsed Multiple Myeloma
Phase 2 Terminated
1 enrolled 11 charts
Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients
Phase 2 Terminated
17 enrolled 5 charts
Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma
Phase 2 Terminated
3 enrolled 6 charts
A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma
Phase 2 Terminated
4 enrolled
Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and/or Smoldering Multiple Myeloma
Phase 2 Terminated
8 enrolled 5 charts
A Trial of TBL12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma
Phase 2 Terminated
20 enrolled 9 charts
PTK/ZK as Post Transplant Maintenance Therapy in Patients With Multiple Myeloma
Phase 2 Terminated
21 enrolled 11 charts
Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match
Phase 2 Terminated
1 enrolled
Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation
Phase 2 Terminated
Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant
Phase 2 Terminated
Arsenic Trioxide, Thalidomide, Dexamethasone, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase 2 Terminated
2 enrolled
Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer
Phase 2 Terminated
5 enrolled 5 charts
D-MP
Phase 2 Terminated
8 enrolled